Abeona Therapeutics ABEO 深 滬
已收盤 04-02 16:00:00 美东时间
4.82
+0.240
+5.24%
華盛通- 最 高4.84
- 今 開4.50
- 成交量 76.66万股
- 最 低 4.50
- 昨 收 4.58
- 總市值 2.75亿
- 52周最高 7.5401
- 市盈率 靜 4.75
- 換手率 1.34%
- 52周最低 4.00
- 委 比 -39.66%
- 總股本 5704.90万
- 歷史最高 750.00
- 量 比 0.73
- 振 幅 7.42%
- 歷史最低 2.19
- 每 手 1
- 風險率 0.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
Abeona Therapeutics Inc. has activated the NewYork-Presbyterian/Columbia University Irving Medical Center as its fifth Qualified Treatment Center (QTC) for ZEVASKYN, a gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB). This expansion enhances patient access in the Northeast, leveraging the institution’s expertise in genetic medicines and skin disorders. ZEVASKYN is the first autologous cell sheet-based gen...
04-02 12:30
Abeona CEO Vishwas Seshadri disposes of ABEO shares worth $0.13 million
Abeona CEO Vishwas Seshadri disposes of ABEO shares worth $0.13 million Abeona Therapeutics CEO Vishwas Seshadri sold 29,985 common shares on March 31, 2026. Sale priced at $4.38 per share on a weighted-average basis. Holdings fell to 1,430,423 shares following transaction. Disclaimer: This news bri
04-01 09:26
Abeona Therapeutics Tightens Shareholder Meeting and Governance Rules
Abeona Therapeutics ( ($ABEO) ) has provided an announcement. On March 16, 2026...
03-21 05:07
Abeona Therapeutics Balances Big Windfall With Slow Ramp
Abeona Therapeutics Inc (($ABEO)) has held its Q4 earnings call. Read on for th...
03-18 08:15
Abeona Therapeutics 2025 net income slightly misses estimates on higher SG&A costs
Abeona Therapeutics 2025 net income slightly misses estimates on higher SG&A costs Overview US biopharma firm's 2025 net income slightly missed analyst expectations Income from operations missed analyst consensus, reflecting higher SG&A costs post-ZEVASKYN launch 2025 revenue reflects first ZEVASKYN
03-17 19:40
Abeona Therapeutics Q4 EPS $(0.34) Beats $(0.36) Estimate, Sales $5.420M Beat $5.270M Estimate
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.36) by 4.49 percent. This is a 142.86 percent decrease over losses of $(0.14) per share
03-17 19:38
Abeona Therapeutics FY2025 SG&A expenses jumped 117.6% to USD 65.03 million
Abeona Therapeutics FY2025 SG&A expenses jumped 117.6% to USD 65.03 million Abeona published a press release reporting full-year 2025 financial results and corporate updates. Total revenue was USD 5.82 million, including USD 2.42 million in net product revenue from a single ZEVASKYN treatment and US
03-17 19:31
Earnings Scheduled For March 17, 2026
Companies Reporting Before The Bell • GDS Holdings (NASDAQ:GDS) is expected to ...
03-17 19:11
Abeona Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates
- First ZEVASKYN commercial patient treatment completed in December; launch momentum building in first quarter 2026 - Abeona reports $191.4M in cash, cash equivalents, and short-term investments as of December 31, 2025 - Total revenue for 2025 was $5.8M, including $2.4M in net product revenue from the first ZEVASKYN treatment - Net income for 2025 was $71.2M, compared to a net loss of $63.7M in 2024 - Cost of sales decreased significantly...
03-17 11:30
美股大行评级 | 潜在涨幅467.73%！Corbus制药控股获Oppenheimer升目标价至57美元，维持"跑赢大市"评级
今日重点评级关注：Oppenheimer：维持Corbus制药控股"跑赢大市"评级，目标价从53美元升至57美元；Canaccord Genuity：维持WAVE Life Sciences"买入"评级，目标价从43美元升至52美元
03-11 12:40
